Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability
Referencias
Additional references
Altman DG, Bland JM. Detecting skewness from summary information.. BMJ 1996;313(7066):706.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
Botts SR, Raskind J. Gabapentin and tiagabine in bipolar disorder. American Journal of Health System Pharmacy 1999;56(19):1939‐44.
Bowden CL. Role of newer medications for bipolar disorder. Journal of Clinical Psychopharmacology 1996;16(2 suppl 1):48‐55.
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double‐blind placebo controlled study of lamotigine montherapy in out‐patients with bipolar 1 depression. Journal of Clinical Psychiatry 1999;60(2):79‐88.
Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double‐blind placebo‐controlled prophylaxis study of lamotrogine in rapid‐cycling bipolar disorder. Journal of Clinical Psychiatry 2000;61(11):841‐50.
De Leon OA. Anti‐epileptic drugs for the acute and maintenance treatment of bipolar disorder. Harvard Review of Psychiatry 2001;9(5):209‐22.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.
Ferrier IN. Tiagabine and gabapentin‐alternatives in the treatment of bipolar disorder. Neuropsychobiology 1998;38(3):192‐7.
Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo‐controlled evaluation of tiagabine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 2000;20(6):607‐14.
Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001;42(Suppl 3):42‐5.
Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. Journal of Clinical Psychiatry 1999;60(11):759‐62.
Ichim L, Berk M, Brook S. Tiagabine compare with lithium in mania: a double‐blind, randomised controlled trial. Annals of Clinical Psychiatry 2000;12(1):5‐20.
Kalviainen R, Noursiainenen I, Mantyjarvi M, et al. Absence of concentric visual field defects in patients with long term tiagabine monotherapy. Neurology 1999;52(Suppl 2):236.
Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Annals of Clinical Psychiatry 1998;10(4):181‐4.
Keck PE, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry 2000;61(Suppl 4):33‐8.
Leach MJ, Marsden CM, Miller AA. Pharmacological studies on tiagabine, a novel potential antiepileptic drug: ii. Neurochemical studies on the mechanism of action. Epilepsia 1986;27(5):490‐7.
Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36(Suppl 6):10‐3.
Leppik IE, Gram L, Deaton R, Sommerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Research 1999;33(2‐3):235‐46.
Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long term tiagabine in epilepsy. Epilepsia 1997;38(8):881‐6.
Maltese T. Adjunctive tiagabine treatment for major depression. American Journal of Psychiatry 1999;156(11):1833.
Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997;349(9063):1436‐42.
Oxman A. Preparing and maintaining systematic reviews. The Cochrane Collaboration Handbook. Oxford: Update Software, 1995.
Sachdeo RC, Leroy RF, Krauss GL, Drake ME, Green PM, Leppik IE, et al. Tiagabine therapy for complex partial seizures. A dose‐frequency study. Archives of Neurology. 1997;54(5):595‐601.
Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The expert consensus guideline series: Medication treatment of bipolar disorder. Postgraduate Medicine 2000;Special Issue:1‐104.
Sackett D. The Cochrane Collaboration Handbook. Oxford: Update Software, 1997.
Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. American Journal of Psychiatry 1999;156(12):2014‐5.
Schaffer LC, Schaffer CB. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. Journal of Affective Disorders 2002;71(1‐3):259‐63.
Suppes T, Chisholm KA, Dhavale D, Frye MA, Altschuler LL, McElroy SL, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disorders 2002;4(5):283‐9.
Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36(6):612‐26.
World Health Organisation. The ICD‐10 Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation, 1992..
